Methamphetamine Causes Differential Alterations in Gene Expression and Patterns of Histone Acetylation/ Hypoacetylation in the Rat Nucleus Accumbens

Tracey A. Martin, Subramaniam Jayanthi, Michael T. McCoy, Christie Brannock, Bruce Ladenheim, Tiffany Garrett, Elin Lehrmann, Kevin G. Becker, Jean Lud Cadet

1 Molecular Neuropsychiatry Research Branch, NIH/NIDA Intramural Research Program, Baltimore, Maryland, United States of America, 2 Gene Expression and Genomics Unit, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States of America

Abstract

Methamphetamine (METH) addiction is associated with several neuropsychiatric symptoms. Little is known about the effects of METH on gene expression and epigenetic modifications in the rat nucleus accumbens (NAC). Our study investigated the effects of a non-toxic METH injection (20 mg/kg) on gene expression, histone acetylation, and the expression of the histone acetyltransferase (HAT), ATF2, and of the histone deacetylases (HDACs), HDAC1 and HDAC2, in that structure. Microarray analyses done at 1, 8, and 24 hrs after the METH injection identified METH-induced changes in the expression of genes previously implicated in the acute and longterm effects of psychostimulants, including immediate early genes and corticotropin-releasing factor (Crf). In contrast, the METH injection caused time-dependent decreases in the expression of other genes including Npas4 and cholecystokinin (Cck). Pathway analyses showed that genes with altered expression participated in behavioral performance, cell-to-cell signaling, and regulation of gene expression. PCR analyses confirmed the changes in the expression of c-fos, fosB, Crf, Cck, and Npas4 transcripts. To determine if the METH injection caused post-translational changes in histone markers, we used western blot analyses and identified METH-mediated decreases in histone H3 acetylated at lysine 9 (H3K9ac) and lysine 18 (H3K18ac) in nuclear sub-fractions. In contrast, the METH injection caused time-dependent increases in acetylated H4K5 and H4K8. The changes in histone acetylation were accompanied by decreased expression of HDAC1 but increased expression of HDAC2 protein levels. The histone acetyltransferase, ATF2, showed significant METH-induced increased in protein expression. These results suggest that METH-induced alterations in global gene expression seen in rat NAC might be related, in part, to METH-induced changes in histone acetylation secondary to changes in HDAC and HDAC expression. The causal role that HATs and HDACs might play in METH-induced gene expression needs to be investigated further.

Introduction

Addiction to methamphetamine (METH) is an international public health problem with an estimated 15–16 million users worldwide. The drug is abused because it is easy to manufacture and is cheaply available [1]. Acute administration of a range of METH doses results in a sense of euphoria, increased energy, and hypersexuality [2]. The acute effects can last for several hrs because of the long elimination half-life and the metabolite profiles of the drug [3]. Injection of the drug to rodents causes increased locomotor activity and stereotypic behaviors [4,5] that are related, in part, to increased levels of dopamine (DA) in the synaptic cleft of brain regions such as the nucleus accumbens (NAC) and the striatum [6] that receive dopaminergic projections from midbrain DA neurons [7]. The drug also causes substantial changes in gene expression in some brain regions including the cortex, the dorsal striatum, and the midbrain [8,9,10,11]. These molecular changes include transient increases and decreases in the expression of various transcription factors, neuropeptides, and genes that participate in several biological functions [8,9,10,11,12,13].

Gene transcription is regulated by complex interactions of transcription factors with regulatory elements [14,15]. During resting states, DNA is compacted in a way that interferes with the binding of transcription factors whereas DNA becomes more accessible during activation of cells by various stimuli [16]. DNA is indeed packaged into chromatin whose fundamental subunit, the nucleosome, is made of 4 core histones, histones H2A, H2B, H3, and H4 that form an octamer (2 of each histone) surrounded by 146 bp of DNA [17]. The N-tails of histones possess lysine residues that can be reversibly acetylated or deacetylated by several histone acetyltransferases (HATs) or by histone deacetylases (HDACs), respectively [18,19]. Other histone modifications that can impact gene expression include methylation, phosphorylation and ubiquitylation [20,21,22]. These changes promote alterations in gene expression by modifying chromatin conformation and enabling or inhibiting recruitment of regulatory factors onto DNA sequences [23].
Therefore, the findings of METH-induced differential changes in gene expression had suggested to us that the drug might also cause changes in histone modifications. In the present study, we focused our attention on whether a single METH injection (20 mg/kg) that induces substantial changes in gene expression might also alter the status of histone acetylation in the rat nucleus accumbens (NAC). Herein, we report that METH administration does trigger time-dependent modifications in the acetylation of histones H3 and H4 as well as increases in ATF2 and HDAC2 expression in the NAC. We discuss the possibility that alterations in histone acetylation might, in part, influence METH-induced changes in gene expression in that brain structure. More direct evidence for a specific role of these histone modifications in mediating METH-induced effects will await further studies using chromatin immunoprecipitation followed by massive parallel sequencing (ChIP-Seq) [24,25].

**Results**

**METH induces changes in gene expression in the NAC**

We performed microarray analyses using Rat Illumina arrays that contain 22, 523 probes to identify genes that are differentially affected at 1, 8, 16, and 24 hrs after a single METH (20 mg/kg) injection that does not cause terminal degeneration in the rat [6]. As expected the METH injection caused significant changes in gene expression in the NAC. Figure 1 shows a Venn diagram depicting the overlap of genes that are altered by METH at the four time points. There were METH-induced changes in expression of 292 genes, with 163 being up-regulated and 127 being down-regulated at the 1-hr time point. IPA analyses revealed that they belong to classes of genes involved in behavioral responses, cell death, cellular development and morphology, cellular growth and proliferation, nervous system development and function, and regulation of gene expression. Figure 2A shows a network of affected genes that are involved in the control of gene expression, cellular growth and proliferation, as well as endocrine functions while Fig. 2B shows genes that are involved cell signaling, cellular development, and nervous system development. Genes of interest include corticotrophin releasing factor (Crf), early growth response 1 (Egr1), early growth response 2 (Egr2), c-fos, homer2, junB, neuronal PAS domain protein 4 (Npas4), nuclear receptor subfamily 4 (Nr4a3), among others (see Table S1 for a longer list).

We used qPCR to confirm the changes in 4 members of the API family of immediate early genes (IEGs). Figure 3 shows that the METH injection caused significant increases [F (6, 26) = 15.30, p<0.0001] in c-fos mRNA levels that were already apparent at 1-hr, peaked at 2-hr (13.6-fold) post-drug injection, and then tapered towards normal 24 hrs later (Fig. 3A). FosB expression also showed METH-mediated increases [F = 12.65, p<0.0001] which were obvious after 1-hr (10.2-fold), peaked at 2-hrs (15.4-fold) after the drug injection, and then reverted back to normal by 24-hr after the drug injection (Fig. 3B). METH caused smaller increases [F = 20.53; p<0.0001] in c-jun expression that peaked at 1-hr (2.5-fold) and then returned to normal levels 8 hrs later (Fig. 3C). There were also METH-induced increases [F = 13.55, p<0.0001] in junB mRNA levels which peaked at 1-hr (10.3-fold) and then tapered towards normal 24 hrs later (Fig. 3D).

In order to identify genes that were affected by METH at later time points, we also performed microarray analyses using tissues from animals euthanized at 8, 16, and 24 hrs after the METH injection. Figure 1 shows the overlap of differentially expressed genes at these three time points. Tables S2, S3, S4 show partial lists of the affected genes. In contrast to the 1-hr time point when more genes showed up-regulation by METH, there were more genes that were down-regulated from 8 to 24 hrs after the single METH injection. For example, there were a total of 304 differentially expressed genes at the 8-hr time point, with 151 being up-regulated and 153 being down-regulated by METH. Pathway analyses revealed that these genes participate in several molecular and cellular functions including cell-to-cell signaling, small molecule biochemistry, and cell death pathways. Some of the genes are also known to participate in behavioral performance, and tissue morphology. Figure S1 shows associated networks that include genes for lipid metabolism, molecular transport, and cellular compromise. Among the METH-regulated genes at the 8-hr time-point were Crf, follistatin (Fst), inhibin beta A (InhbA), and neuromedin U (Nmnu) (Table S2). At the 16-hr time after drug injection, 170 genes were affected by METH, with 74 being up- and 96 being down-regulated. These genes are known to participate in several biological functions including protein synthesis, cell signaling, and nervous system development. Figure S2 shows a network that contains genes related to cellular assembly and organization, cellular movement, and nervous system function. At 16 hrs post-drug, genes of interest that show up-regulation included tumor necrosis factor superfamily alpha (TNF-alpha), and Nmu (Table S3). At the 24-hr time point, METH caused differential expression in 197 genes, with 63 being up- and 134 being down-regulated. These genes belong to classes of genes that participate in cell signaling, molecular transport, and nervous system development. Figure S3 shows a network that contains genes involved in cellular growth and proliferation, cell death, nervous system development, and behavior. Down-regulated genes include BDNF, Cck, Npas4, among others (Table S4). As shown in Figure 1, there were 14 genes that were affected at both the 1- and 8-hr time point. These genes that include Crf participate in endocrine system function, and lipid metabolism. There were 35 genes that were similarly affected at both 8- and 16-hr after the METH injection. IPA shows that these genes regulated cellular development, cellular compromise, and cell-to-cell signaling. In addition, 29 genes were similarly affected at the 16- and 24-hr time points. These are involved in cell-to-cell signaling, developmental disorders, molecular transport, and the regulation of gene expression.

**Figure 1. A single injection of METH (20 mg/kg) caused time-dependent changes in gene expression in the NAC.** The Venn diagram depicts the overlap of genes identified in the four time points (1-hr, 8-hr, 16-hr and 24-hr) after administration of a single, non-toxic dose (20 mg/kg) of METH. RNA was extracted from NAC and the microarray experiments were performed as described in the methods section. Genes were identified as significantly changed if they show greater than ±1.7-fold changes at p<0.05. doi:10.1371/journal.pone.0034236.g001
Networks of METH-induced changes in gene expression one hour after the drug injection. Networks of related genes were identified using Ingenuity Pathway Analysis (IPA) software. Figure 2A shows a network of affected genes that are involved in the control of gene expression, cellular growth and proliferation as well as endocrine functions while Figure 2B shows genes that are involved in that are involved cell signaling, cellular development, and nervous system development. Relationships are shown as lines and arrows. Genes colored pink to red are up-regulated whereas those colored light to deep green are down-regulated, with the intensity of the color representing greater magnitude of changes.

Discussion

Recent studies have shown that a single administration of METH can have prolonged behavioral, biochemical, and molecular effects in rodents [6,12,13,29]. However, the molecular underpinnings for these long-term effects of this drug have yet to be fully elucidated. As an initial step in a program of studies to clarify the molecular bases of METH-induced complex changes in the brain, the present study investigated the time course of potential METH-induced changes in gene expression and histone modifications in the NAC, a structure that is closely tied to the behavioral effects of psychostimulants [30]. We thus used a dose of METH that does not cause any persistent toxicity in the brain [6] to measure potential prolonged global changes in gene expression in that structure.

Among other genes, we identified Crf as one gene that was substantially induced in the NAC. CRF, a polypeptide composed of 41 amino acids, is the major regulator of the pituitary-adrenal axis [31]. CRF has been shown to trigger various biochemical and behavioral changes in animals [32,33,34]. For example, infusion of CRF by itself into the NAC caused increased locomotor activity [35]. The behavioral effects are most probably due to the widespread distribution of CRF and of its receptors in the mammalian brain [36,37,38,39]. The acute METH-induced increases in Crf expression are interesting because dysregulation of processes regulated by CRF have been implicated in addiction to illicit drugs [32,40]. Our results are also consistent with the report that binge cocaine administration can also cause increases in Crf in rat brain [41] and suggest that psychostimulants of diverse classes can cause increases in Crf mRNA levels. Of related interest, low doses of CRF can potentiate stereotypic behaviors caused by amphetamine [42], suggesting an additional role of
Figure 3. METH caused changes in the expression of transcription factors and neuropeptides in the NAC. The graphs show the effects of METH on transcript levels for (A) c-fos, (B) fosb, (C) c-jun, (D) junB, (E) Crf, (F) Nmu, (G) Cck, and (H) Npas4 mRNA levels at various time points after injection of the drug. The rats were injected with a single injection of METH as described in the method section. Total RNA was extracted from the NAC and used in qPCR assays. The relative amounts of transcripts were normalized to OAZ1 (ornithine decarboxylase antienzyme 1). Statistical significance was determined by ANOVA followed by post-hoc tests. Key to statistics (n=5–8 animals per group): * = p<0.05; ** = p<0.01; *** = p<0.001, in comparison to the control group.

doi:10.1371/journal.pone.0034236.g003
METH-induced Alterations in Histone Acetylation

Figure 4. METH induced significant decreases in H3K9 and H3K18 acetylation in the NAC. The graphs show representative results from Western blot analyses using specific antibodies against (A) H3K9ac and H3K18ac (C) at various time points after injection of the drug. The rats were injected with a single injection of METH as described in the method section. Western blot analyses were carried out as described in the Method section. The relative amounts of proteins were normalized to tubulin. The bar graphs show quantification of the effects of METH on (B) H3K9ac and (D) H3K18ac, respectively. Statistical significance was determined by ANOVA followed by post-hoc tests. Key to statistics (n=6 rats per group): * = p<0.05; ** = p<0.01; *** = p<0.001, in comparison to the control group.

doi:10.1371/journal.pone.0034236.g004

Figure 5. METH caused significant increases in H4K5 and H4K8 acetylation in the NAC. The graphs show representative results from Western blot analyses using specific antibodies against (A) H4K5ac and (C) H3K18 at various time points after injection of the drug. The rats were injected with a single injection of METH as described in the method section. Western blot analyses were carried out as described in the Method section. The relative amounts of proteins were normalized to tubulin. The bar graphs show quantification of the effects of METH on (B) H4K5ac and (D) H4K8ac, respectively. Statistical significance was determined by ANOVA followed by post-hoc tests. Key to statistics (n=6 rats per group): * = p<0.05; ** = p<0.01; *** = p<0.001, in comparison to the control group.

doi:10.1371/journal.pone.0034236.g005
CRF in behaviors induced by amphetamine analogs. Cocaine was also shown to induce CRF receptor-dependent hyperlocomotion [43]. Importantly, Moffett and Goeders (2007) [44] recently reported that CP-154–526, a CRF type-1 receptor antagonist, was able to attenuate METH-induced reinstatement of extinguished METH-seeking behaviors in the rat. The METH-induced increases in CRF expression might be related to the fact that the drug injection caused downregulation of HDAC1 expression in the nuclear fraction of the NAC since HDAC1 up-regulation has been reported to cause downregulation of CRF expression [45].

In contrast to the METH-increases in CRF mRNA levels, we found substantial decreases in Cck mRNA levels that lasted through the duration of the experiments. The neuropeptide, CCK, is synthesized as a pre-pro-hormone that is cleaved to produce several peptides [46] including the main neurotransmitter, CCK-8, which is involved in a number of behavioral and biological functions [47]. CCK is widely distributed in the rodent brain [48,49] and co-localizes with several neurotransmitters including dopamine [50,51]. CCK is located within vesicles [49] from which it can be released [52]. There also exists an interesting literature on the role of CCK on dopamine-mediated behaviors, with different subregions of the NAC showing differential effects on DA-mediated locomotor activity [53]. For example, Crawley et al. (1985) [54] reported that injection of DA into the NAC caused dose-dependent increases in locomotor activity. Injection of CCK alone had no effects on locomotor responses. However, co-administration of CCK with DA potentiated DA-induced hyperlocomotion. Subsequent studies revealed involvement of CCK-A and CCK-B receptors in the mediation of DA-induced hyperlocomotion in the medial posterior NAC and anterior NAC, respectively [55]. On the other hand, Weiss et al., (1988) [56] reported that injections of CCK into the NAC antagonized amphetamine-induced hyperlocomotion. CCK also antagonized apomorphine-induced hyperlocomotion [57]. Nevertheless, our observations of METH-induced decreases in Cck mRNA levels suggest that injection of METH might have caused co-release of CCK and DA from midbrain projections to the NAC [50] and that local CCK-containing cell bodies [48,49] might have compensated to the overstimulation of CCK receptors by decreasing Cck transcript levels. This idea is consistent with the report that amphetamine caused DA release that was accompanied with a rapid and transient CCK release in the NAC with a peak response within the first 20 min after the drug injection [58]. The timing of the AMPH-induced release of CCK is consistent with the decreases in Cck mRNA levels and with the suggested possibility that the observed decreased Cck transcript levels are potentially compensatory to METH-induced CCK release. Our results are also consistent with the report that a single dose of a lower dose of METH (0.5 mg/kg) [59] or daily METH injections for 14 days [60] caused decreases in Cck mRNA levels in the rat brain.

The accumulated evidence indicates that increases in gene expression are associated with increases in histone acetylation whereas decreases in gene expression correlate with hypoacetylation of histones [61,62]. Histone H4 acetylation enables regulatory proteins to access DNA and plays a major role in regulating gene expression [63,64]. The substantial METH-induced increases of histone H4K5 and H4K8 acetylation are, thus, of interest because both H4K5 and H4K8 belong to the class of so-called “common modification module” that is present on active and poised promoters [65], thus suggesting that METH might have influenced the composition of this module. The increases in H4K5 and H4K8 acetylation might be secondary to the METH-induced increases in the expression of ATF2 that has HAT activity [66] for histone 4 [28]. ATF-2 is a member of the ATF/CREB family of transcription factors that contain a common basic region leucine zipper (bZIP) [67]. The family members that include...
ATF1, ATF2, ATF3, ATF4, and CREB, among others can homodimerize or heterodimerize with members of other bZIP-containing proteins including members of the API family of transcription factor [68]. ATF-2 itself, can heterodimerize with c-Jun [69] and c-Fos [70]. ATF-2 has been shown to bind to both the AP-1 site (TGACTCA) and the CRE site (TG/AACGTCA) [68,71]. As mentioned above, ATF-2 possesses intrinsic histone acetyltransferase (HAT) activity on histone H4 and promotes CRE-dependent transcription [72]. A potential role for ATF2 in METH-induced H4 acetylation is consistent with our findings that the increases in ATF2 preceded H4K5 and H4K8 acetylation after the METH injection. Because ATF2 HAT activity has been shown to be necessary for CRE-dependent transcription [72], it is fair to propose that the delayed increases in gene expression after a single injection of METH might be due, in part, to increases in H4K5 and H4K8 acetylation secondary to METH-induced increases in ATF2 expression. It is important to note that the METH-induced increased in H4K5 acetylation could also be due to the drug-induced decreases in HDAC1 expression observed in the nuclear fractions obtained from the NAC because RNAi-mediated reduction in HDAC1 nuclear staining was reported to induce increases in H4K5 acetylation [73]. The authors also reported that RNAi-induced decreases in HDAC1 expression were accompanied by increased HDAC2 expression, which we also observed after the single injection of METH (Fig. 7C). Although the specific role for ATF2, HDAC1, and H4K5ac in the regulation of specific target genes will have to depend on future studies using chromatin precipitation followed by massive parallel sequencing (ChIP-Seq) in order to provide genome-scale quantification of ATF2- and HDAC1-, and H4K5ac-DNA binding [24,25], these investigations are beyond the scope of the present paper. Nevertheless, it is notable that some known ATF2 target genes including c-fos and c-jun [74,75] did show METH-induced increases (see Figure 3B and 3C, respectively). Similarly, CRF whose expression is downregulated by increased HDAC1 expression [45] showed significant increases (Fig. 3E) after the METH injection that caused decreases in HDAC1 expression in the nuclear fraction of the NAC (see Fig. 7A). These caveats, notwithstanding, our present observations provide additional support for the proposal that changes in gene regulation that occur after exposure to illicit substance such as cocaine might be consequences of alterations in histone modifications [76,77]. Future studies in this laboratory will seek to determine the role of specific histone modifications in acute and chronic METH-induced changes in gene expression in the brain.

Our experiments also showed that METH caused substantial time-dependent decreases in the acetylation of histone H3K9, H3K18, and H4K16. These changes in histone acetylation are consistent with our demonstration that METH also caused substantial increases in HDAC2 protein levels in the NAC. Indeed, recruitment of HDAC proteins to the promoters of genes is known to cause histone hypoacetylation and subsequent transcriptional repression of various genes [78,79], including neuronal genes [80,81]. Therefore, the observed METH-induced histone hypoacetylation in H3K9 and H3K18 might offer a partial explanation for the METH-induced repression of many genes observed at 8, 16, and 24 hrs after the single METH injection, with a larger number of genes being down-regulated than up-regulated at the 8-hr, 16-hr and 24-hr time points. Although previous studies have focused mainly on the role of the cAMP/PKA/CREB pathway [82] in psychostimulant-induced changes in gene expression [11], the present study identifies increases in HDAC2, but decreased H3K9ac and H3K18ac expression as potentially effectors of METH-induced repression of genes that were affected both early and late during the course of the present experiments. This idea is consistent with the report that HDAC inhibition caused potentiation of kainate-induced increases in c-fos and c-jun expression [83]. Finally, the greater number of repressed genes observed at the 24-hr time point might be due, in part, to the concomitant METH-induced decreases in pCREB expression that occurred at that time.
In summary, our data identify, for the first time, the existence of concomitant increases and decreases in the expression of many genes in the rat NAC after a single METH injection. These changes in gene expression were associated with diverse alterations in histone acetylation. These observations are consistent with previous demonstrations that histone modifications can participate in crosstalks [84,85] that regulate gene expression in a complex fashion [65,86,87]. Our findings also suggest that studies of the effects of psychostimulants need to take into consideration the combinatorial roles of histones in their control of gene expression [65]. Our study also supports the notion that modulators of histone acetylation might be attractive therapeutic players against various diseases including addiction to licit and illicit substances. Although more studies are needed to determine the specific manner by which METH-induced changes in ATP2, HDACs, and histone acetylation might differentially influence the levels of specific transcripts, our data suggest that a single METH exposure can cause profound alterations in the molecular machinery of the brain. Finally, even though the present study aimed to provide an initial look at the effects of METH on histone acetylation, future studies will investigate the effects of the drug on other histone modifications because understanding the molecular impact of these combinatorial alterations might lead to better therapeutic strategies against the adverse effects of psychostimulant use.

**Materials and Methods**

**Animals and Drug treatment**

Male Sprague-Dawley rats (Charles River Labs, Raleigh, NC, USA), weighing 375±25 g, were used in the experiments. Rats were housed in a temperature-controlled (22.2±0.2 °C) room with free access to food and water. The animals received a single injection of METH (20 mg/kg) and were euthanized at various time points afterwards. This METH dose has been used in behavioral and biochemical experiments and has been shown robust increases in DA release in the NAC [6] (6). All animal use procedures were according to the NIH Guide for the Care and Use of Laboratory Animals and were approved by the National Institute of Drug Abuse–/Intramural Research Program (IRP) Animal Care and Use Committee (NIDA/IRP-ACUC).

**Tissue collection and RNA extraction**

At the indicated time after the METH or saline injections, rats (n = 5 per group) were euthanized and the NAC was dissected and immediately put on dry ice. Total RNA was isolated from the nucleus accumbens according to the manufacturer’s manual using Qiagen RNeasy mini kit (Qiagen, Valencia, CA, USA). RNA integrity was detected using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). The antibodies used were anti-acetyl-histone H4K8 (Lys 8), H4K12 (Lys 12), and H4K16 (Lys 16) (Millipore, Billerica, MA, USA); anti-HDAC1 and anti-HDAC2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA); anti-phospho-CREB and anti-ATF2 (Cell Signaling Technology, Danvers, MA, USA). To confirm equal protein loading, blots were re-probed with β-tubulin antibody (1:4000; Sigma, 2 h at RT). LumiGLO chemiluminescent reagents (Cell Signaling Technology Inc., Danvers, MA, USA) were used to detect protein expression. Signal intensity was measured densitometrically with LabWorks version 4.5 (Biorad Imaging Systems software, Bio Imaging System, UWP Inc., Upland, CA). For quantification, the signal intensity was normalized using the signal intensity of tubulin (n = 6 per group).

**Statistical Analyses**

Data for quantitative PCR and Western blot analyses are presented as means ± SEM. Statistical analyses were performed using one-way ANOVA analysis followed by Fisher’s protected least significant difference (StatView 4.02, SAS Institute, Cary, NC). Criteria for significance were set at p<0.05.

**Supporting Information**

**Figure S1** A network of genes whose expression was affected by METH at 8-hr after the injection of the drug.

**Figure S2** A network of genes whose expression was affected by METH at 16-hr after the injection of the drug.

**Figure S3** A network of genes whose expression was affected by METH at 24-hr after injection of the drug.
Networks of related genes were identified using Ingenuity Pathway Analysis (IPA) software. The figure shows genes involved in the regulation of cell death, nervous system development, and cell proliferation. Relationships are shown as lines and arrows. Color schemes are as described in figure 2.

**Figure S4** Methadone administration caused significant decreases in H4K16 acetylation in the NAC. The graph shows representative results from Western blot analyses using a specific antibody against (A) H4K16ac at various time points after the injection of the drug. Western blot analyses and statistical analyses were carried out as described in Fig. 4. The bar graph shows quantification of the effects of METH on H4K16ac. Key to statistics: *p < 0.05; **p < 0.01; ***p < 0.001, in comparison to the control group.

**Table S1** Partial list of METH-upregulated genes measured at 1-hr after the drug injection. The list of genes was generated as described in the text. The genes are listed in descending order according to METH-induced fold changes in transcript levels.

**Table S2** Partial list of METH-regulated genes measured at 8-hr after the drug injection. The genes are listed in descending order according to METH-induced fold changes in gene expression.

**References**

1. Krausova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379–407.
2. Barr AM, Penenka MJ, Maretta GW, Thornton AE, Lang DJ, et al. (2006) The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci 31: 301–313.
3. Schepers RJ, Oyler JM, Joseph RE, Jr., Cone JE, Moohchan ET, et al. (2003) Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 49: 121–132.
4. Frankel PS, Hoomakker AJ, Danaceau JP, Hanson GR (2007) Mechanism of an exaggerated locomotor response to a low-dose challenge of methamphetamine. Pharmacol Biochem Behav 86: 513–515.
5. Hall DA, Stanis Jj, Marquez Avila H, Gulley JM (2008) A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl) 195: 469–478.
6. Xi ZX, Kleite HK, Deng X, Ladenheim B, Peng QX, et al. (2009) A single high dose of methamphetamine increases cocaine self-administration by depletion of striatal dopamine in rats. Neuroscience 161: 392–402.
7. Björling A, Dumett SB (2007) Dopamine neuron systems in the brain: an update. Trends Neurosci 30: 194–202.
8. Cadet JL, Krausova IN, Ladenheim B, Cai NS, McCoy MT, et al. (2009) Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain. Neurotox Res 15: 252–259.
9. Cadet JL, Jayanthi S, McCoy MT, Vawter M, Ladenheim B (2001) Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain. Evidence from cDNA array. Synapse 41: 40–48.
10. Thomas DM, Francescatti-Verberme DM, Lau X, Kuhn DM (2004) Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment—an oligonucleotide microarray approach. J Neurochem 83: 380–393.
11. Cadet JL, Jayanthi S, McCoy MT, Beauvais G, Cai NS (2010) Dopamine D1 Receptors. Regulation of Gene Expression in the Brain, and Neurodegeneration. CNS Neurol Disord Drug Targets.
12. Jayanthi S, Deng X, Ladenheim B, McCoy MT, Chater A, et al. (2005) Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci U S A 102: 841–845.
13. Jayanthi S, McCoy MT, Beauvais G, Ladenheim B, Gilmore K, et al. (2009) Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum. PLoS One 4: e4902.
14. Belotserkovskaya R, Saunders A, Lis JT, Reinberg D (2004) Transcription through chromatin: understanding a complex FACT. Biochim Biophys Acta 1677: 87–99.
15. Razin SV, Iarovaia OV, Spakse N, Spakse T, Bagdoniene L, et al. (2007) Chromatin domains and regulation of transcription. J Mol Biol 369: 597–607.
16. Bano M (1996) Chromatin structure and the regulation of gene expression: remodeling at the MIVTM promoter. J Mol Med (Berl) 74: 711–724.
17. Randu OJ, Ahmad K (2007) Rules and regulation in the primary structure of chromatin. Curr Opin Cell Biol 19: 250–256.
18. Campos EL, Reingberg D (2009) Histones: annotating chromatin. Annu Rev Genet 43: 559–599.
19. Morrison BE, Majda wold M, D’Mello SR (2007) Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64: 2250–2260.
20. Berger SI (2010) Cell signaling and transcriptional regulation via histone phosphorylation. Cold Spring Harb Symp Quant Biol 75: 23–26.
21. Hublitz P, Albert M, Peters AH (2009) Mechanisms of transcriptional repression by histone lysine methylation. Int J Dev Biol 53: 335–354.
22. Osley MA, Fleming AB, Kao CF (2006) Histone ubiquitinylation and the regulation of transcription. Results Probl Cell Differ 41: 47–75.
23. Verdine L, Agricola E, Caserta M, Di Mauro E (2006) Histone acetylation in gene regulation. Brief Funct Genomic Proteomic 5: 209–221.
24. MacQuarrie KL, Fong AP, Morse RH, Tapscott SJ (2011) Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet 27: 141–148.
25. Northrup DL, Zhao K (2011) Application of ChIP-Seq and related techniques to the study of immune function. Immunity 34: 830–842.
26. Keppler BK, Archer TK (2000) Chromatin-modifying enzymes as therapeutic targets: Part 2. Expert Opin Ther Targets 12: 1457–1463.
27. Mayer PC, Morgan BA, Mitzman BA, Smith MM (1990) Genetic analysis of histone H4: essential role of lysines subject to reversible acetylation. Science 247: 841–845.
28. Bruhat A, Cherasse Y, Maurin AC, Beuninzerw W, Parry L, et al. (2007) ATF2 is required for amino acid-regulated transcription by orchestrating specific histone acetylation. Nucleic Acids Res 35: 1312–1321.
29. Thiriet N, Deng X, Solinas M, Ladenheim B, Curtis W, et al. (2005) Neuroptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci 25: 5273–5279.
30. Luscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: Part 2. Expert Opin Ther Targets 15: 1437–1463.
31. Uhlmann E, Holscher HD (2009) Epigenetic silencing of the steroidalogenic acute regulatory (star) gene: a double-negative transcriptional circuitry. J Cell Biochem 106: 1062–1071.
32. Koob GF, Zorrilla EP (2010) Neurobiological mechanisms of addiction: focus on the brain: Evidence from cDNA array. Synapse 41: 40–48.
33. Megee PC, Morgan BA, Mitzman BA, Smith MM (1990) Genetic analysis of histone H4: essential role of lysines subject to reversible acetylation. Science 247: 841–845.
34. Brubach A, Cherasse Y, Maurin AC, Beuninzerw W, Parry L, et al. (2007) ATF2 is required for amino acid-regulated transcription by orchestrating specific histone acetylation. Nucleic Acids Res 35: 1312–1321.
35. Thiriet N, Deng X, Solinas M, Ladenheim B, Curtis W, et al. (2005) Neuroptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J Neurosci 25: 5273–5279.
36. Luscher C, Malenka RC (2011) Drug-evoked synaptic plasticity in addiction: Part 2. Expert Opin Ther Targets 15: 1437–1463.
37. Uhlmann E, Holscher HD (2009) Epigenetic silencing of the steroidalogenic acute regulatory (star) gene: a double-negative transcriptional circuitry. J Cell Biochem 106: 1062–1071.
38. Megee PC, Morgan BA, Mitzman BA, Smith MM (1990) Genetic analysis of histone H4: essential role of lysines subject to reversible acetylation. Science 247: 841–845.
39. Brubach A, Cherasse Y, Maurin AC, Beuninzerw W, Parry L, et al. (2007) ATF2 is required for amino acid-regulated transcription by orchestrating specific histone acetylation. Nucleic Acids Res 35: 1312–1321.
40. Shalev Y, Erb S, Shaham Y (2010) Role of CRF and other neuropeptides in corticotropin-releasing factor. Curr Opin Investig Drugs 11: 63–71.
41. Morley JL, Levine AS (1982) Corticotropin releasing factor, grooming and ingestive behavior. Life Sci 31: 1459–1464.
42. Shalev Y, Erb S, Shaham Y (2010) Role of CRF and other neuropeptides in corticotropin-releasing factor-induced remission of drug seeking. Brain Res 1314: 15–28.

**Author Contributions**

Wrote the paper: JLC. Designed the experiments: JLC. Wrote the animal protocol: SJ. Performed Western blot: TAM. Performed Western blot analyses: SJ. Performed drug injections and the dissection of rat brains: BL. Performed the quantitative PCR analyses: TG. Performed the Ilumina bead array experiments: EL. Provided guidance for the Illumina bead array experiments: KB. Analyzed the western data: TAM. Analyzed the quantitative PCR data: TG. Analyzed the microarray data: CB. Performed bio-informatics analyses: MTM. Helped to write the manuscript: SJ.
35. Holsahan MR, Kalin NH, Kelley AE (1997) Microfusion of corticotropin-releasing factor into the nucleus accumbens shell results in increased behavioral arousal and oral motor activity. Psychopharmacology (Berl) 130: 189–196.
36. De Souza EB, Insel TR, Perrin MH, Rivier J, Vale WW, et al. (1985) Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system: an autoradiographic study. J Neurosci 5: 3189–3203.
37. Perrin MH, Vale WW (1999) Corticotropin releasing factor receptors and their ligand family. Annu Rev Neurosci 22: 513–540.
38. Pratim KS, Yeciesh C, Bahalzar C, Gudger DW (1997) Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain. Neuropharmacology 36: 308–316.
39. Sawchenko PE, Imaki T, Potter E, Kwacs K, Imaki, et al. (1993) The functional anatomy of corticotropin-releasing factor. Ciba Found Symp 172: 5–21, discussion 21–29.
40. Sarnyai Z, Shaham Y, Heinrichs SC (2001) The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53: 209–243.
41. Zhou Y, Spangler R, LaForge KS, Magos CE, Ho A, et al. (1996) Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during “binge”-pattern cocaine withdrawal. J Pharmacol Exp Ther 279: 351–358.
42. Cole BJ, Koob GF (1989) Low doses of corticotropin-releasing factor potentiate amphetamine-induced stereotyped behavior. Psychopharmacology (Berl) 99: 27–33.
43. Liu L, Liu Z, Huang M, Zhang Z (2003) Dopamine-dependent responses to CRF depend on corticotropin-releasing factor receptor subtypes. J Neurochem 84: 1378–1386.
44. Moffett MC, Goeders NE (2002) CP-154,526, a CRF type-1 receptor agonist, attenuates the cue and methamphetamine-induced reinstatement of extinguished methamphetamine-seeking behavior in rats. Psychopharmacology (Berl) 190: 171–180.
45. Miller L, Foradori CD, Lalmasingham AS, Sharma D, Hanja R, et al. (2011) Histone deacetylase (HDAC1) participates in the down-regulation of corticotropin releasing hormone gene (CRH) expression. Physiol Behav 104: 312–320.
46. Beinfeld MC (2003) Biosynthesis and processing of pro CCK: recent progress. Peptides 24: 471–473.
47. Crawley JN, Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15: 471–473.
48. Beinfeld MC (2003) Biosynthesis and processing of pro CCK: recent progress. Peptides 24: 471–473.
49. Vanderhaeghen JJ, Lotstra F, Demey J, Gilles C (1980) Immunohistochemical localization of Cholecystokinin-Like and Gastrin-Like Peptides in the Brain and Hypophysis of the Rat. Proceedings of the National Academy of Sciences of the United States of America-Biological Sciences 77: 1190–1194.
50. Serogy KB, Dangurang K, Lim S, Haycock JW, Fallon JH (1989) Ventral mesencephalic neurons containing both cholecystokinin- and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J Comp Neurol 289: 397–414.
51. Serogy KB, Melta A, Fallon JH (1987) Neutrotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain. Exp Brain Res 66: 277–289.
52. Emson PC, Lee CM, Rehfeld JF (1980) Cholecystokinin octapeptide: vesicular transport and binding. Nature 284: 619–621.
53. Ura K, Kurumizaka H, Dimitrov S, Almouzni G, Wolffe AP (1997) Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-histone-dependent transcriptional repression. EMBO J 16: 2096–2107.
54. Liu L, Hua J, Pruss D, Wolffe AP (1993) A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 72: 73–84.
55. Rundlett SE, Carmen AA, Suka N, Turner BM, Grunstein M (1998) Transcriptional repression by UME3 involves deacetylation of lysine 3 of histone H4 by RPD3. Nature 399: 833–837.
56. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, et al. (2008) Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 40: 857–903.
57. Kawasaki H, Schiltz L, Chin R, Bakara K, Taika K, et al. (2000) ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature 405: 195–200.
58. Hai T, Hartman MG (2001) The molecular biology and nomenclature of the activating transcription factor-1/AMP responsive element binding family of transcription factors: activating transcription factor proteins and homoeostasis. Gene 273: 1–11.
59. van Dam H, Castelazzi M (2001) Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis. Oncogene 20: 2453–2464.
60. De Crespe V, Vallen D, Caracciolo A, Sassone-Corsi P, Neveel C, et al. (1995) Histone acetylation and nucleosome remodeling by H3 and histone H4. EMBO J 14: 3720–3724.
61. Abdel-Hafiz HA, Heasley LE, Kyriakos JM, Avruch J, Kroll DJ, et al. (1992) Activating transcription factor-2 DNA-binding activity is stimulated by phosphorylation catalyzed by p53 and p54 nucleotide-associated protein kinases. Mol Endocrinology 6: 981–989.
62. Kawasaki H, Taika K, Yokoyama K (2000) Histone acetyltransferase (HAT) activity of ATF-2 is necessary for the CRE-dependent transcription. Nucleic Acids Symp Ser pg. 259–260.
63. Ma P, Schulte RM (2008) Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos. Dev Biol 319: 110–120.
64. Liu H, Deng X, Shuy VJ, Li J, Taparovski EJ, et al. (2006) Mutual regulation of c-jun and ATF2 by transcriptional activation and subcellular localization. EMBO J 25: 1058–1069.
65. Lopez-Bergami P, Lau E, Ronai Z (2010) Emerging roles of ATF2 and the dynamic API network in cancer. Nat Rev Cancer 10: 65–76.
66. Rehalth W, Kumar A, Xiao G, Wilkinson M, Covington HE, et al. (2009) Genome-wide analysis of chromatin regulation by cocaine reveals a role for sirtnoms. Neuron 62: 335–348.
67. Rehalth W, Neister EJ (2009) Histone acetylation in drug addiction. Semin Cell Dev Biol 20: 387–394.
68. Khan AN, Tomasi TB (2008) Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res 40: 164–178.
69. Shahbazian MD, Grunstein M (2007) Functions of site-specific histone acetylation and transcription. Annu Rev Biochem 76: 75–100.
70. Huang Y, Myers SJ, Dingledine R (1999) Transcriptional repression by REST: recruitment of Smi3A and histone deacetylase to neuronal genes. Nat Neurosci 2: 867–872.
71. Naruse Y, Aoki T, Kojima T, Mori N (1999) Neural restrictive silent factor recruits mSin3 and histone deacetylase complex to repress neuron-specific target genes. Proc Natl Acad Sci U S A 96: 13691–13696.
72. De Cesare D, Sassone-Corsi P (2000) Transcriptional regulation by cyclic AMP-responsive factors. Prog Nucleic Acid Res Mol Biol 64: 343–369.
73. Sug NJ, Tanisira H, Yoneda Y (2006) Inhibition of histone deacetylation by trichostain A amplifies the transcriptional activities of neuronal c-fos and c-jun genes after dopamine withdrawal. Neurosci Lett 396: 130–135.
74. Fischl W, Wang Y, Allis CD (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15: 172–183.
75. Winter S, Fischl W (2010) Epigenetic markers and their cross-talk. Essays Biochem 48: 45–61.
76. Murr R (2010) Interplay between different epigenetic modifications and mechanisms. Adv Genet 70: 101–141.
77. Wang Z, Cai G, Cui K, Zhang D, Barski A, et al. (2009) Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138: 1019–1031.
78. Cadet JL, Brannock C, Krasnov IN, Ladebrown B, McCoy MT, et al. (2010) Methamphetamine-induced dopamine-independent alterations in striatal gene expression in the 6-hydroxydopamine hemiparkinsonian rats. PLoS One 5: e15643.
79. Cadet JL, Brannock C, Ladebrown B, McCoy MT, Beavani G, et al. (2011) Methamphetamine preconditioning causes differential changes in striatal transcription factor receptors to large doses of the drug. Dose Response 9: 165–181.
80. McCoy MT, Jayanthi S, Wulu JA, Beauvais G, Ladenheim B, et al. (2011) Chronic methamphetamine exposure suppresses the striatal expression of members of multiple families of immediate early genes (IEGs) in the rat striatum: normalization by an acute methamphetamine injection. Psychopharmacology (Berl) 215: 353–363.